Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran 300 mg in ASCVD or ASCVD-risk equivalents with elevated LDL-C (Germany)
2017-001846-90Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Aug 2017
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and atherosclerotic disease comparing Inclisiran 300 mg with Placebo (2 arms). Started Aug 2017; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on 2017-001846-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001846-90.